Annovis Bio corrects 2025 audit fees to $415,000, total fees $515,000
Annovis Bio corrected its 2025 audit fee disclosure, reporting $415,000 in audit fees and $515,000 in total fees to Ernst & Young LLP. This is an increase from $375,000 in audit fees and $482,045 in total fees in 2024. The correction was filed via Form 8-K.
How this was made
The 30-second read
Why it matters
The correction updates audit‑fee figures but does not alter the company's financial outlook.
Market read
Minor filing with negligible trading relevance.
What to watch
The filing confirms Ernst & Young remains the auditor; no change in auditor relationship.
Background
Annovis Bio (ANVS) filed a Form 8‑K to correct a typographical error in its proxy regarding audit fees for the 2025 annual meeting.
Ticker impact
Form 8‑K filed to correct audit‑fee numbers for 2025, updating the disclosed total to $515,000.
likely little to no price movement as the change is purely clerical.
Amounts are small for a public biotech and the market typically treats fee corrections as non‑material.
Market effects
none
none
none
Counterpoint
Investors could view the correction as a sign of tighter financial controls, but impact remains minimal.
Key entities
- companyAnnovis Bio
US‑listed biotech issuing the correction.
- service_providerErnst & Young LLP
Auditor receiving the corrected fees.
